市场调查报告书
商品编码
1554521
Componen(3D 生物列印机、支架、生物材料)、应用(研究、临床)、最终用户(医院、研究组织和学术机构、生物製药公司)和地区的日本 3D 生物列印市场报告 2024-2032Japan 3D Bioprinting Market Report by Componen (3D Bioprinters, Scaffolds, Biomaterials), Application (Research, Clinical), End User (Hospitals, Research Organization and Academic Institutes, Biopharmaceuticals Companies), and Region 2024-2032 |
日本3D生物列印市场规模预计在2024-2032年期间呈现16.73%的成长率(CAGR)。老年人口对器官移植的需求不断增加,以及获得医疗技术的便利性,主要推动了市场的成长。
三维 (3D) 生物列印是一种积层製造技术,专为精确製造解剖组织而开发。此方法涵盖各种沉积和组装工艺,包括直接写入和雷射写入、微冲压、光刻、立体光刻、电子印刷和喷墨沉积。除此之外,它还依靠基于细胞的生物墨水的逐层组装来构建3D组织和器官结构,这些生物墨水是使用活细胞、生物材料和活性生物分子配製而成的。透过沉积多层生物材料,3D 生物列印可以创建复杂的身体结构,如骨骼、皮肤、软骨、血管移植物、气管夹板和心臟组织。因此,它在日本各地的医院、研究机构、学术机构和生物製药公司中得到了广泛的应用。
在日本市场背景下,越来越重视减少动物试验是对该行业产生积极影响的重要因素。此外,对3D生物列印的需求不断增长,特别是在更容易患各种慢性疾病的老年族群中,正在培育良好的市场前景,从而成为另一个重要的成长诱导因素。除此之外,晶片器官系统的开发等技术进步也正在推动市场成长。此外,全球对再生医学、癌症治疗和干细胞解决方案的需求不断增长,也促进了市场的扩张。除此之外,日本的医疗保健产业越来越多地采用3D生物列印,与其他产业相比,其干扰程度相对较低,为市场成长提供了大力支持。此外,知名製造商非常重视旨在推出生物印刷纸巾的研发(R&D)活动,这对区域市场产生了正面影响。这项努力旨在降低与新创新相关的成本并简化药物发现流程,进一步推动日本国内的进步。所有上述因素预计将在预测期内促进市场成长。
IMARC Group提供了每个细分市场的主要趋势分析,以及 2024-2032 年国家层级的预测。我们的报告根据组件、应用程式和最终用户对市场进行了分类。
该报告根据组成部分提供了详细的市场细分和分析。这包括 3D 生物列印机(注射器/挤出生物列印、喷墨生物列印、磁悬浮生物列印、雷射辅助生物列印等)、支架和生物材料(活细胞、水凝胶、细胞外基质等)。
报告还提供了基于应用程式的详细市场细分和分析。这包括研究(药物研究、再生医学和 3D 细胞培养)和临床(皮肤、骨骼和软骨、血管等)。
该报告提供了基于最终用户的详细市场细分和分析。这包括医院、研究机构和学术机构以及生物製药公司。
该报告还对所有主要区域市场进行了全面分析,包括关东地区、关西/近畿地区、中部/中部地区、九州冲绳地区、东北地区、中国地区、北海道地区和四国地区。
市场研究报告也对竞争格局进行了全面分析。报告涵盖了市场结构、关键参与者定位、最佳制胜策略、竞争仪表板和公司评估象限等竞争分析。此外,也提供了所有主要公司的详细资料。
此处未提供公司名称,因为这是目录范例。报告中提供了完整的清单。
Japan 3D bioprinting market size is projected to exhibit a growth rate (CAGR) of 16.73% during 2024-2032. The elevating need for organ transplantation among the geriatric population, along with the easy access to medical technologies, is primarily driving the market growth.
Three-dimensional (3D) bioprinting is an additive manufacturing technique developed for the precise fabrication of anatomical tissues. This method encompasses various deposition and assembly processes, including direct and laser writing, microstamping, photolithography, stereolithography, electro-printing, and inkjet deposition. In addition to this, it relies on the layer-by-layer assembly of cell-based bio-inks, which are formulated using living cells, biomaterials, and active biomolecules, to construct 3D tissue and organ structures. By depositing multiple layers of biomaterials, 3D bioprinting can create complex bodily structures such as bones, skin, cartilage, vascular grafts, tracheal splints, and heart tissues. Consequently, it finds extensive applications in hospitals, research institutions, academic establishments, and biopharmaceutical companies across Japan.
In the context of the Japan market, the increasing emphasis on reducing animal testing is a significant factor positively influencing the industry. Additionally, the rising demand for 3D bioprinting, particularly among the elderly population who are more susceptible to various chronic illnesses, is fostering a favorable market outlook, thereby acting as another significant growth-inducing factor. Besides this, technological advancements such as the development of organ-on-a-chip systems are also driving market growth. Furthermore, the surging global demand for regenerative medicines, cancer therapeutics, and stem cell solutions is contributing to the expansion of the market. Apart from this, the healthcare sector in Japan is increasingly adopting 3D bioprinting, and its relatively lower disruption level compared to other industries is providing substantial support to market growth. Moreover, prominent manufacturers are placing a strong focus on research and development (R&D) activities aimed at introducing bio printed tissues, which is positively influencing the regional market. This effort aims to reduce the cost associated with new innovations and streamline the drug discovery process, further propelling advancement within Japan. All these above mentioned factors are expected to catalyze the market growth over the forecasted period.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on component, application, and end user.
The report has provided a detailed breakup and analysis of the market based on the component. This includes 3D bioprinters (syringe/extrusion bioprinting, inkjet bioprinting, magnetic levitation bioprinting, laser-assisted bioprinting, and others), scaffolds, and biomaterials (living cells, hydrogels, extracellular matrices, and others).
A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes research (drug research, regenerative medicine, and 3D cell culture) and clinical (skin, bone and cartilage, blood vessels, and others).
The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, research organization and academic institutes, and biopharmaceuticals companies.
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Company names have not been provided here as this is a sample TOC. The complete list is provided in the report.